By 2025 we aspire to be one of the largest pure play vaccines companies, improving and saving lives by excelling in R&D innovation, manufacturing and commercialization.
This vision is carried by three strategic pillars:
- a company driven by commercial excellence
- to develop innovative life-saving vaccines
- best in class vaccine manufacturer
Establish a full-scale commercial operation to expand the business and drive profitable growth
Following the acquisition of Rabipur/RabAvert and Encepur and the FDA approval of JYNNEOS, Bavarian Nordic has an ambition to expand its operations to include a full commercial organization. The acquisition creates the opportunity to establish a scaled commercial organization that is synergistic to JYNNEOS for the monkeypox indication.
Expand and advance portfolio of pipeline projects
Bavarian Nordic sees the continued progression of the development pipeline as of strategic importance with the aim to develop lifesaving vaccines. Key pipeline priorities are development and approval of the freeze-dried version of the smallpox vaccine, development and approval of an RSV vaccine, and to advance other infectious diseases and immunotherapy projects.
Expand manufacturing expertise and capacity
Bavarian Nordic wants to further leverage its expertise within manufacturing of live virus vaccines. This involves completing the manufacturing footprint to encompass the full value chain from bulk manufacturing to fill and finish, as well as increasing bulk capacity and introducing the flexibility to manufacture different bulk vaccines in parallel. All of this with the strategic aim to be a best-in-class vaccine manufacturer.